Printed From BioPortfolio.com

NICE recommends Novartis' Extavia for MS, but knocks back a raft of other beta interferons

05:22 EST 20 Dec 2017 | Pharmafile

NICE has revealed that it has passed draft guidance that recommends Novartis’ Extavia (interferon beta 1b) for the treatment of relapsing- remitting multiple sclerosis (MS) or secondary progressive MS with continued relapses in adult patients, provided on the NHS in England and Wales.

Original Article: NICE recommends Novartis' Extavia for MS, but knocks back a raft of other beta interferons

More From BioPortfolio on "NICE recommends Novartis' Extavia for MS, but knocks back a raft of other beta interferons"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches